Pharmacogenetics of Resistance to Cisplatin and Other Anticancer Drugs and the Role of Sphingolipid Metabolism

Overview

Journal Methods Mol Biol

Specialty Molecular Biology

Date 2013 Mar 16

PMID 23494308

Citations 1

Authors

Stephen Alexander

William S Swatson

Hannah Alexander

Affiliations

Soon will be listed here.

Abstract

Dictyostelium discoideum has proven to be a useful lead genetic system for identifying novel genes and pathways responsible for the regulation of sensitivity to the widely used anticancer drug cisplatin. Resistance to cisplatin is a major factor limiting the efficacy of the drug in treating many types of cancer. Studies using unbiased insertional mutagenesis in D. discoideum have identified the pathway of sphingolipid metabolism as a key regulator in controlling sensitivity to cisplatin. Using the genetic tools including directed homologous recombination and ectopic gene expression available with D. discoideum has shown how pharmacological modulation of this pathway can increase sensitivity to cisplatin, and these results have been extensively translated to, and validated in, human cells. Strategies, experimental conditions, and methods are presented to enable further study of resistance to cisplatin as well as other important drugs.

Citing Articles

Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.

Amnekar R, Khan S, Rashid M, Khade B, Thorat R, Gera P World J Gastroenterol. 2020; 26(6):598-613.

PMID: 32103870 PMC: 7029347. DOI: 10.3748/wjg.v26.i6.598.

References

Williams R, Boeckeler K, Graf R, Muller-Taubenberger A, Li Z, Isberg R . Towards a molecular understanding of human diseases using Dictyostelium discoideum. Trends Mol Med. 2006; 12(9):415-24. DOI: 10.1016/j.molmed.2006.07.003. View

Faix J, Kreppel L, Shaulsky G, Schleicher M, Kimmel A . A rapid and efficient method to generate multiple gene disruptions in Dictyostelium discoideum using a single selectable marker and the Cre-loxP system. Nucleic Acids Res. 2004; 32(19):e143. PMC: 528815. DOI: 10.1093/nar/gnh136. View

King J, Insall R . Parasexual genetics using axenic cells. Methods Mol Biol. 2006; 346:125-35. DOI: 10.1385/1-59745-144-4:125. View

Li G, Foote C, Alexander S, Alexander H . Sphingosine-1-phosphate lyase has a central role in the development of Dictyostelium discoideum. Development. 2001; 128(18):3473-83. DOI: 10.1242/dev.128.18.3473. View

Glockner G, Eichinger L, Szafranski K, Pachebat J, Bankier A, Dear P . Sequence and analysis of chromosome 2 of Dictyostelium discoideum. Nature. 2002; 418(6893):79-85. DOI: 10.1038/nature00847. View

Williams R . Pharmacogenetics in model systems: defining a common mechanism of action for mood stabilisers. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29(6):1029-37. PMC: 1249490. DOI: 10.1016/j.pnpbp.2005.03.020. View

Wernyj R, Morin P . Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat. 2004; 7(4-5):227-32. DOI: 10.1016/j.drup.2004.08.002. View

Min J, Mesika A, Sivaguru M, Van Veldhoven P, Alexander H, Futerman A . (Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1. Mol Cancer Res. 2007; 5(8):801-12. DOI: 10.1158/1541-7786.MCR-07-0100. View

Van Veldhoven P . Sphingosine-1-phosphate lyase. Methods Enzymol. 1999; 311:244-54. DOI: 10.1016/s0076-6879(00)11087-0. View

10.

Adley K, Keim M, Williams R . Pharmacogenetics: defining the genetic basis of drug action and inositol trisphosphate analysis. Methods Mol Biol. 2006; 346:517-34. DOI: 10.1385/1-59745-144-4:517. View

11.

Oskouian B, Sooriyakumaran P, Borowsky A, Crans A, Dillard-Telm L, Tam Y . Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer. Proc Natl Acad Sci U S A. 2006; 103(46):17384-9. PMC: 1859938. DOI: 10.1073/pnas.0600050103. View

12.

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

13.

Sridevi P, Alexander H, Laviad E, Min J, Mesika A, Hannink M . Stress-induced ER to Golgi translocation of ceramide synthase 1 is dependent on proteasomal processing. Exp Cell Res. 2009; 316(1):78-91. PMC: 2791511. DOI: 10.1016/j.yexcr.2009.09.027. View

14.

Eichinger L, Pachebat J, Glockner G, Rajandream M, Sucgang R, Berriman M . The genome of the social amoeba Dictyostelium discoideum. Nature. 2005; 435(7038):43-57. PMC: 1352341. DOI: 10.1038/nature03481. View

15.

Dubin M, Nellen W . A versatile set of tagged expression vectors to monitor protein localisation and function in Dictyostelium. Gene. 2010; 465(1-2):1-8. DOI: 10.1016/j.gene.2010.06.010. View

16.

Sridevi P, Alexander H, Laviad E, Pewzner-Jung Y, Hannink M, Futerman A . Ceramide synthase 1 is regulated by proteasomal mediated turnover. Biochim Biophys Acta. 2009; 1793(7):1218-27. PMC: 2724657. DOI: 10.1016/j.bbamcr.2009.04.006. View

17.

Min J, Stegner A, Alexander H, Alexander S . Overexpression of sphingosine-1-phosphate lyase or inhibition of sphingosine kinase in Dictyostelium discoideum results in a selective increase in sensitivity to platinum-based chemotherapy drugs. Eukaryot Cell. 2004; 3(3):795-805. PMC: 420124. DOI: 10.1128/EC.3.3.795-805.2004. View

18.

Sussman M . Cultivation and synchronous morphogenesis of Dictyostelium under controlled experimental conditions. Methods Cell Biol. 1987; 28:9-29. DOI: 10.1016/s0091-679x(08)61635-0. View

19.

Alexander S, Alexander H . Lead genetic studies in Dictyostelium discoideum and translational studies in human cells demonstrate that sphingolipids are key regulators of sensitivity to cisplatin and other anticancer drugs. Semin Cell Dev Biol. 2010; 22(1):97-104. DOI: 10.1016/j.semcdb.2010.10.005. View

20.

Alexander H, Vomund A, Alexander S . Viability assay for Dictyostelium for use in drug studies. Biotechniques. 2003; 35(3):464-6, 468, 470. DOI: 10.2144/03353bm05. View